3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Esophageal Neoplasms
1
Adenocarcinoma
1
Interventions
Fluorouracil
286
Oxaliplatin
274
Gemcitabine
222
Capecitabine
221
Leucovorin
219
Bevacizumab
200
Irinotecan
170
pembrolizumab
141
Cisplatin
132
Cetuximab
111
Radiotherapy
109
Sorafenib
75
Nivolumab
75
130-nm albumin-bound paclitaxel
64
Paclitaxel
63
Albumin-Bound Paclitaxel
63
Docetaxel
61
Erlotinib Hydrochloride
57
Panitumumab
56
Radiosurgery
47
Folfox protocol
46
regorafenib
45
Sunitinib
40
Radiation
39
Magnetic Resonance Spectroscopy
38
durvalumab
33
Surgical Procedures, Operative
33
Ramucirumab
33
Trastuzumab
32
Cyclophosphamide
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
matuzumab
×
Gastrointestinal
×
Clear all
NCT00215644
2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
72 enrolled
7 charts